Dr. Marc Lang

Marc has a PhD in Chemistry and more than 30 years of experience in medicinal chemistry in the pharmaceutical industry at Novartis. During his career, he contributed personally to three compounds currently on the market: Femara® (aromatase inhibitor); Reyataz® (HIV-protease inhibitor); Tasigna® (Bcr/Abl kinase inhibitor) and several promising compounds still in clinical trials. He currently is a scientific advisor to several pharmaceutical companies.

Previous member Next member